Thermo Fisher has flourished amid the pandemic, but can it keep the ball rolling when Covid-19 comes to a close?
Amid a gangbusters 12 months for contract manufacturers, Thermo Fisher Scientific saw a massive revenue bump in Q1 — and that’s without considering its $17.4 billion buyout of contract researcher PPD. But Covid-19 won’t last forever, and analysts wonder when and if Thermo Fisher will come back to earth.
On an earnings call with analysts Thursday, CEO Marc Casper pointed to a string of recent investments — the PPD acquisition obviously the largest — as a sign that Thermo is leveraging its gushing cash flow to put itself in a position to succeed even once the pandemic comes to an end. The company posted 59% revenue growth on the quarter to $9.91 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.